Key Points
- Apogee Therapeutics CEO Michael Thomas Henderson sold 20,000 shares on June 10 at an average price of $83.38, totaling about $1.67 million. The sale was made under a pre-arranged Rule 10b5-1 plan.
- After the transaction, Henderson still owned 1,095,987 shares valued at roughly $91.4 million, and the sale reduced his position by 1.79%. He had also sold 20,000 shares in each of the prior two reported transactions in April and May.
- Apogee shares were down 1.3% on the day and recently traded near the top of their 52-week range. Analysts remain mostly bullish, with a Moderate Buy consensus and an average price target of $114.56.
Apogee Therapeutics Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $83.38, for a total transaction of $1,667,600.00. Following the transaction, the chief executive officer directly owned 1,095,987 shares in the company, valued at approximately $91,383,396.06. The trade was a 1.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Michael Thomas Henderson also recently made the following trade(s):
- On Wednesday, May 13th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $82.09, for a total value of $1,641,800.00.
- On Wednesday, April 8th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $82.58, for a total value of $1,651,600.00.
Apogee Therapeutics Stock Down 1.3%
Shares of APGE stock opened at $88.33 on Friday. Apogee Therapeutics Inc. has a 12 month low of $34.34 and a 12 month high of $95.32. The business's 50 day moving average is $84.47 and its two-hundred day moving average is $77.33. The company has a market cap of $5.47 billion, a PE ratio of -20.40 and a beta of 0.62.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, May 11th. The company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.01. As a group, equities analysts expect that Apogee Therapeutics Inc. will post -4.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Apogee Therapeutics
Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. acquired a new stake in shares of Apogee Therapeutics in the 4th quarter valued at $25,000. ANTIPODES PARTNERS Ltd raised its stake in shares of Apogee Therapeutics by 41.2% in the third quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company's stock worth $33,000 after acquiring an additional 246 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in shares of Apogee Therapeutics during the fourth quarter worth approximately $37,000. EverSource Wealth Advisors LLC lifted its position in shares of Apogee Therapeutics by 61.7% during the first quarter. EverSource Wealth Advisors LLC now owns 645 shares of the company's stock worth $54,000 after purchasing an additional 246 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in shares of Apogee Therapeutics during the third quarter worth approximately $96,000. Institutional investors and hedge funds own 79.04% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on APGE. Mizuho raised their price objective on shares of Apogee Therapeutics from $105.00 to $110.00 and gave the stock an "outperform" rating in a research note on Monday, March 30th. BTIG Research restated a "buy" rating and issued a $137.00 price objective on shares of Apogee Therapeutics in a research note on Wednesday, May 27th. Citigroup boosted their price objective on Apogee Therapeutics from $95.00 to $125.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Guggenheim boosted their price objective on Apogee Therapeutics from $130.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Finally, Canaccord Genuity Group boosted their price objective on Apogee Therapeutics from $89.00 to $130.00 and gave the company a "buy" rating in a research report on Tuesday, March 24th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $114.56.
View Our Latest Stock Report on Apogee Therapeutics
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.
The company's lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
